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Abstract. Regenerative medicines that promote remyelination in multiple sclerosis (MS) are making 
the transition from laboratory to clinical trials. While animal models provide the experimental flex-
ibility to analyse mechanisms of remyelination, here we discuss the challenges understanding 
where and how remyelination occurs in MS. 
The modern era has seen a burgeoning interest in stem cells and their potential to transform regen-
erative medicine. The regeneration of new myelin sheaths (remyelination) in demyelinating-neuro-
degenerative diseases such as multiple sclerosis (MS) has emerged as one of the more promising di-
rections for therapeutic intervention. Much of this optimism stems from an increased understanding 
of the process of remyelination and the identification of an abundant progenitor cell population, com-
monly referred to as oligodendrocyte progenitor cells or OPCs, in the adult mammalian CNS capable 
of generating new oligodendrocytes in experimental models of demyelination  (Zawadzka et al., 2010). 
Based on these findings, most current research aimed at developing remyelination medicines has in-
volved finding ways to pharmacologically induce OPCs to differentiate into oligodendrocytes 
(Deshmukh et al., 2013).  
While it is now beyond doubt that in animal models of demyelination/remyelination new myelin 
sheaths can be made oligodendrocytes newly-generated from adult OPCs, there is also evidence from 
animal models that new myelin sheaths can also be generated by existing oligodendrocytes without 
the need for de novo oligodendrogliogenesis (Duncan et al., 2018). But what do we know of the gen-
eration of new myelin sheaths in MS, where the dynamics of a regenerative process are considerably 
harder to infer? The possibility that myelin regeneration in MS can occur without the need for the 
generation of new oligodendrocytes has come from a study that takes advantage of fluctuations in 
atmospheric 14C levels. These peaked during the 1950s and 1960s (when the testing of atomic bombs 
was at its most prevalent) and which has subsequently declined towards pre-testing levels, making it 
possible to ‘birth date’ cells based on their 14C content.  This approach indciates that there is a minimal 
degree of de novo generation of oligodendrocytes in healthy adult human white matter (Yeung et al., 
2014), and, surprisingly, in areas of the MS brain where remyelination was thought to have occurred 
(Yeung et al., 2019). Thus, the proposed model is that mature oligodendrocytes, once shorn of their 
myelin sheath-bearing processes, can generate new myelin sheaths that survive within an MS lesion. 
The possibility that this mode of remyelination might also exist in humans is intriguing and certainly 
requires further investigation, not least for its therapeutic potential — and in this regard, studies that 
have aimed to foster oligodendrocyte survival in the face of acute demyelinating insult are sure to be 
of great importance.  
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However, in studies that aim to elucidate the nature of remyelination in human disease, a critical issue 
is whether remyelination (which by definition will have been preceded by primary demyelination) can 
be reliably identified. The uncertainties that continue to exist in the unambiguous identification of 
remyelination by MRI or other imaging approaches are well recognised are discussed elsewhere 
(Petiet et al., 2019). Identifying remyelination in tissue sections is felt to be more straightforward, and 
it is widely accepted that an area where the intensity of myelin stains is lower than expected — re-
ferred to in human neuropathology as a ‘shadow plaque’ — indicates remyelination. But how valid is 
this assumption? In this commentary, we argue that not all shadow plaques are necessarily areas of 
remyelination, and that not all areas of remyelination are necessarily shadow plaques, and suggest 
that a reappraisal of the relationship between remyelination and the shadow plaque is urgently 
needed to avoid making unjustified inferences about the nature of remyelination in the human CNS.  
Why are shadow plaques thought to represent areas of remyelination? 
The basis for identifying remyelination in post-mortem MS tissue derives from animal experiments 
where it is possible to unambiguously show first the loss of myelin from axons and second the rein-
vestment of the denuded axons with new myelin sheaths. Some of the earliest experimental studies 
of remyelination were conducted using the cuprizone model, in which a systemic toxin that preferen-
tially kills oligodendrocytes is fed to mice, and involved examination of the mouse cerebellar pedun-
cles that contain relatively large diameter axons (Blakemore, 1973). These studies revealed that a car-
dinal feature of remyelination is that the new myelin sheath is thinner than expected for the axonal 
diameter. This characteristic of remyelination is convenient because the identification of thin myelin 
sheaths (often expressed as an increase in the ratio of the diameter of the myelinated axons to the 
axon alone, also known as the g-ratio) provides a very reliable means of inferring that remyelination 
has taken place (notwithstanding that there may be other causes for alterations in g-ratios, such as 
axonal swelling or thinning of the sheath). Indeed, demonstration of thin myelin sheaths has become 
the gold standard for identifying sites of remyelination. This means that because there is less total 
myelin in a remyelinated area it will appear paler when stained with a myelin marker, such as Luxol 
fast blue or Eriochrome cyanine. On this basis, pale staining areas of white matter in MS tissue (often 
referred to as shadow plaques) are generally assumed to be areas of remyelination. However, ultra-
structural verification of thin myelin sheaths within these areas has been very limited, given the in-
herent difficulties in obtaining human post-mortem samples that are sufficiently well-preserved in 
patients where lesions have been tracked over time using in vivo MRI.   
Will all areas of remyelination necessarily appear as shadow plaques?  
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Subsequent studies in white matter areas containing smaller diameter axons, such as the corpus cal-
losum, revealed that the difference between the g-ratio of myelination and remyelination becomes 
much less clear the smaller the axon diameter (Stidworthy et al., 2003). This means that areas of re-
myelination are likely to look similar to surrounding intact white matter and are therefore very difficult 
to detect. Indeed, lesions detectable by MRI can subsequently appear normally myelinated when 
viewed by immunohistochemistry for myelin proteins (Trapp et al., 2018). A further factor that is likely 
to contribute to areas of remyelination being missed is that a significant degree of resolution (i.e. 
return to pre-lesion appearance) occurs in remyelinated areas over time. Although g-ratios may never 
return to normal, especially in areas containing large diameter axons, there is some remodelling of 
the new myelin sheaths, and eventually the area of remyelination can very closely resemble the sur-
rounding white matter. Figure 1 shows a lysolecithin-induced demyelinating lesion in the white matter 
of the adult mouse spinal cord ventral funiculus (an area containing many large diameter axons) 150 
days after induction. The lesion is nearly fully resolved, and it is a challenge to delineate where the 
remyelinated area ends and the normal white matter begins, even with optimal tissue fixation and 
processing that is rarely, if ever, achieved with human post-mortem tissue. Although this is a toxin 
model of demyelination whose cause is different from demyelination in MS, it illustrates why areas of 
remyelination may not resemble a classical shadow plaque and could easily be overlooked. Indeed, 
substantial generation of new oligodendrocytes was observed in so-called normal appearing white 
matter (NAWM) of some of the MS patients reported in the MS 14C dating study (Yeung et al., 2019). 
Specifically, in the NAWM in 10 out of 20 patients, the oligodendrocyte turnover was 20–80%, which 
is significantly higher than the oligodendrocyte turnover in non-diseased tissue. Given that there is 
little oligodendrocyte exchange in healthy adult human white matter (Yeung et al., 2014), it is likely 
that these are areas of resolved OPC-mediated remyelination not easily distinguishable from NAWM.  
Are all shadow plaques areas of remyelination?  
Although thinner myelin sheaths may well result in paler myelin staining, there are several other pro-
cesses that would have the same effect. These include any process that decreases axonal density, such 
as tissue expansion due to inflammatory infiltrates, oedema, and astrocytosis following axonal loss (a 
well-recognised feature of both acute and chronic MS lesions and even of distant white matter via the 
process of Wallerian degeneration). Even a finding of thin myelin sheaths need not necessarily indicate 
that remyelination has taken place, as pathological axonal swelling can lead to a stretching and thin-
ning of the original myelin sheath, which might in itself contribute to paler myelin staining. Thus, areas 
of myelin pallor described as shadow plaques may represent areas that have never undergone primary 
demyelination and therefore cannot be areas of remyelination.  
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What can we infer from tissue samples about dynamic biological processes? 
Modelling the dynamics of remyelination, independent of whether remyelination is OPC- or oligoden-
drocyte-derived, is difficult in MS tissue. Most importantly, it is usually unknown when a lesion oc-
curred in MS patients. Dating the lesion age, regardless of when the disease first manifests clinically, 
is impossible to establish. Lesions may have occurred and resolved before the age of diagnosis, just as 
they may have occurred years, even decades, after diagnosis — especially in the era prior to highly 
effective disease-modifying therapy, which began in the mid-1990s. Moreover, in the 1950s and 
1960s, formal diagnosis of MS often occurred long after symptoms began, which is much more rarely 
the case today. The inability to define the lesion age makes the 14C dating of cells driving remyelination 
in MS lesions very challenging (an issue acknowledged in the study by Yeung et al., 2019). In this re-
spect, it would of interest to combine extended pre-mortem MRI follow-up with post-mortem birth 
dating of oligodendrocytes in both lesions and NAWM (as has been done using primate models of MS). 
Being agnostic about the history of lesions is also problematic for approaches based on single cell 
sequencing (Jäkel et al., 2019). A higher expression of myelin genes in a cell identified as a mature 
oligodendrocyte according to expression of key marker genes may indicate that a pre-existing oli-
godendrocyte engaged in remyelination. However, an increased expression of myelin genes is also a 
hallmark of newly formed oligodendrocytes that differentiated from OPCs. Pseudotime analysis is of-
ten used to circumvent this problem, and to establish a possible timeline of cellular fates. However, 
while this is a powerful tool to generate hypotheses about the dynamics of a biological process from 
a single snapshot in time, experimental validation is still needed to establish that distinct cellular states 
with functional heterogeneity exist and that differentiating cells actually follow the bioinformatically 
predicted trajectories.  
Remyelination therapies in multiple sclerosis - too soon to give up on progenitors? 
Thus, the data that currently exist, including that using 14C dating, point to a picture of remyelination 
in humans where there is some remyelination mediated by OPCs, especially in lesions that formed 
early in the disease. Given that the degree of lesion resolution is likely to be much greater than cur-
rently recognised, the extent to which this occurs is very difficult to assess at present. With disease 
progression and ageing, where the age-related decline in OPC function leads to a decline in remye-
lination efficiency, this mode of remyelination might be superseded by a different mode of remye-
lination mediated by surviving oligodendrocytes (Duncan et al., 2018). The possibility of novel and 
previously unrecognised means of remyelination is undoubtedly immensely invigorating for the field 
and warrants further experimental investigations. However, it would be unjustified and harmful for 
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the development of much needed regenerative therapies for progressive MS if we were to throw the 
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Figure 1: Areas of demyelination that undergo remyelination resolve with time. Representative im-
ages of lysolecithin-induced lesions in the ventral funiculus of the adult mouse spinal cord stained with 
toluidine blue. (a) 21 days and (b) 150 days after lesion induction.  Scale bar = 50µm. 
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